Cargando…

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic di...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisondi, Paolo, Geat, Davide, Maurelli, Martina, Degli Esposti, Luca, Bellinato, Francesco, Girolomoni, Giampiero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142895/
https://www.ncbi.nlm.nih.gov/pubmed/35632402
http://dx.doi.org/10.3390/vaccines10050646
_version_ 1784715672293474304
author Gisondi, Paolo
Geat, Davide
Maurelli, Martina
Degli Esposti, Luca
Bellinato, Francesco
Girolomoni, Giampiero
author_facet Gisondi, Paolo
Geat, Davide
Maurelli, Martina
Degli Esposti, Luca
Bellinato, Francesco
Girolomoni, Giampiero
author_sort Gisondi, Paolo
collection PubMed
description Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease. Methods: The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy. The 52-week primary endpoint was the American College of Rheumatology response rate (ACR) 20; secondary endpoints were ACR 50, Psoriasis Area and Severity Index (PASI) 90, and minimal disease activity (MDA). Results: The cost per responder for ACR 20 was €19,846 versus €19,766 for secukinumab and adalimumab, respectively, whereas the costs per responder for ACR 50 and PASI 90 were €27,820 versus €27,384 and €22,102 versus €32,375 for secukinumab and adalimumab, respectively. The cost per MDA responder was €34,072 and €38,906 for secukinumab versus adalimumab. Conclusions: The costs per responder associated with the psoriatic arthritis end points were similar for adalimumab and secukinumab; conversely, the costs for psoriasis and composite end points were lower for secukinumab.
format Online
Article
Text
id pubmed-9142895
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91428952022-05-29 Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease Gisondi, Paolo Geat, Davide Maurelli, Martina Degli Esposti, Luca Bellinato, Francesco Girolomoni, Giampiero Vaccines (Basel) Article Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease. Methods: The cost per responder was calculated by multiplying the cost of treatment by the number needed to treat for each therapy. The 52-week primary endpoint was the American College of Rheumatology response rate (ACR) 20; secondary endpoints were ACR 50, Psoriasis Area and Severity Index (PASI) 90, and minimal disease activity (MDA). Results: The cost per responder for ACR 20 was €19,846 versus €19,766 for secukinumab and adalimumab, respectively, whereas the costs per responder for ACR 50 and PASI 90 were €27,820 versus €27,384 and €22,102 versus €32,375 for secukinumab and adalimumab, respectively. The cost per MDA responder was €34,072 and €38,906 for secukinumab versus adalimumab. Conclusions: The costs per responder associated with the psoriatic arthritis end points were similar for adalimumab and secukinumab; conversely, the costs for psoriasis and composite end points were lower for secukinumab. MDPI 2022-04-20 /pmc/articles/PMC9142895/ /pubmed/35632402 http://dx.doi.org/10.3390/vaccines10050646 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gisondi, Paolo
Geat, Davide
Maurelli, Martina
Degli Esposti, Luca
Bellinato, Francesco
Girolomoni, Giampiero
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
title Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
title_full Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
title_fullStr Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
title_full_unstemmed Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
title_short Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
title_sort cost per responder analysis of secukinumab versus adalimumab in the treatment of psoriatic disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142895/
https://www.ncbi.nlm.nih.gov/pubmed/35632402
http://dx.doi.org/10.3390/vaccines10050646
work_keys_str_mv AT gisondipaolo costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease
AT geatdavide costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease
AT maurellimartina costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease
AT degliespostiluca costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease
AT bellinatofrancesco costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease
AT girolomonigiampiero costperresponderanalysisofsecukinumabversusadalimumabinthetreatmentofpsoriaticdisease